Biological perspectives - Serotonin and norepinephrine reuptake inhibitors (SNRIs): Venlafaxine and duloxetine

Perspectives in Psychiatric Care

Volumn 42, Issue 2, 2006, Pages 144-148

  Lee, Stacey I ^a   Keltner, Norman L ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR AFFECTING AGENT; CYCLOHEXANOL DERIVATIVE; DULOXETINE; NORADRENALIN; SEROTONIN UPTAKE INHIBITOR; THIOPHENE DERIVATIVE; VENLAFAXINE;

ADULT; CASE REPORT; FEMALE; HUMAN; MAJOR DEPRESSION; METABOLISM; REVIEW;

ADRENERGIC UPTAKE INHIBITORS; ADULT; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; NOREPINEPHRINE; SEROTONIN UPTAKE INHIBITORS; THIOPHENES;

EID: 33645839287     PISSN: 00315990     EISSN: 17446163     Source Type: Journal    
DOI: 10.1111/j.1744-6163.2006.00064.x     Document Type: Review

References (17)

1. Ayd F.J. 1991 The early history of modern psychopharmacology Neuropsychopharmacology 5 2 71 84
2. Clerc G.E. Ruimy P. Verdeau-Pailles J. 1994 A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia International Clinical Psychopharmacology 9 138 143
3. Cunningham L.A. The Venlafaxine XR 208 Study Group. ( 1997 Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression Annals of Clinical Psychiatry 9 3 157 164
4. Goldstein D.J. Mallinckrodt C. Lu Y. Demitrack. 2002 Duloxetine in the treatment of major depressive disorder: A double-blind clinical trial Journal of Clinical Psychiatry 63 3 225 231
5. Keltner N.L. Folks D.G. 2005 Psychotropic drugs
6. Montgomery S.A. Entsuah R. Hackett D. Kunz N.R. & Rudolph R.L. for the Venlafaxine 335 Study Group. 2004 Venlafaxine versus placebo in the preventive treatment of recurrent major depression Journal of Clinical Psychiatry 65 328 336
7. Posternak M.A. Zimmerman. 2005 Dual reuptake inhibitors incur lower rates of tachyphylaxis than selective serotonin reuptake inhibitors: A retrospective study Journal of Clinical Psychiatry 66 6 705 707
8. Reynaert-Dupuis C. Zdanowicz N. 2002 Efficacy and tolerance of venlafaxine in depressed patients switched from prior antidepressant treatment Primary Care Psychiatry 8 2 63 68
9. Shelton R.C. 2004 The dual-action hypothesis: Does pharmacology matter? Journal of Clinical Psychiatry 65 Suppl.17 5 10
10. Thase M.E. for the Venlafaxine XR 209 Study Group. 1997 Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression Journal of Clinical Psychiatry 58 9 393 398
11. Thase M.E. 2004 Introduction, The dual-action debate: Does pharmacology matter? Journal of Clinical Psychiatry 65 Suppl.17 3 4
12. Thase M.E. Entsuah A.R. & Rudolph R.L. 2001 Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors British Journal of Psychiatry 178 234 241
13. The Medical Letter on Drugs and Therapeutics. 2004 Duloxetine (Cymbalta): A new SNRI for depression Medical Letter on Drugs and Therapeutics 46 81 82
14. The Medical Letter on Drugs and Therapeutics. 2005 Duloxetine (Cymbalta) for diabetic neuropathic pain Medical Letter on Drugs and Therapeutics 47 67 68
15. Vis P.M.J. van Baardewijk M. Einarson T.R. 2005 Duloxetine and venlafaxine-XR in the treatment of major depressive disorder: A meta-analysis of randomized clinical trials The Annals of Pharmacotherapy 39 11 1798 1807
16. Wyeth Inc 2005 Effexor XR approved for the treatment of panic disorder Retrieved November 26, 2005, from and November 2005 from #Cymbalta
17. Zajecka J.M. Albano D.A. 2004 SNRIs in the management of acute major depressive disorder Journal of Clinical Psychiatry 65 Suppl.17 11 18